This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trends In Therapeutic Partnering

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Trends in Therapeutic Partnering https://www.reportbuyer.com/product/1593890/Trends-in-Therapeutic-Partnering.html The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014.The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2009 to mid 2014. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2007, together with insight into which companies are active in each of the thirty five leading therapeutic areas.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.The initial chapters of this report provide an orientation of therapeutic dealmaking.Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of therapeutic dealmaking since 2009, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2009-2014 according to reported deal size.Chapter 4 provides a summary on best practice on how to submit an opportunity to the leading therapeutic partnering companies, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.Chapter 5 lists forthcoming partnering events where valuable face to face meetings with biopharma companies provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.The main body of the report is provided in chapter 6. In-depth profiles of each of the top 35 therapeutic target areas according to deal frequency during the period 2009-2014 provide everything required to assess the potential of the therapeutic area and its active partner companies. Each profile includes a partnering activity overview, deal financials (including headline, upfront and royalties rates, where available).Each therapeutic profile provides a listing of partnering deals for the top fifiteen most active companies in each therapeutic area, and is accompanied by an appendix that provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.This data driven report contains over 5,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.In summary, the report provides the reader with the tools necessary to understand trends in therapeutic partnering, the most active therapeutic areas in terms of deal frequency and leading deal maker companies, and the deal terms and structures achieved in such therapeutic partnering deals. Report scopeTrends in Therapeutic Partnering is intended to provide the reader with an in-depth understanding of therapeutic partnering trends and structure of deals entered into by leading companies worldwide. Trends in Therapeutic Partnering includes:Trends in therapeutic dealmaking in the biopharma industry since 2009Analysis of therapeutic partnering deal structureAccess to over 5,000 therapeutic partnering dealsThe top 35 therapeutic targets for partnering since 2009The leading therapeutic partnering deals by value since 2009Most active therapeutic partnering dealmakers since 2009 In Trends in Therapeutic Partnering, the available deals are listed by:Most active companies in partnering for each therapeutic areaHeadline valueUpfront paymentRoyalty rateCompany A-ZEach deal title links to online deal records of actual therapeutic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.The Trends in Therapeutic Partnering report provides comprehensive access to available deal records for over 5,000 therapeutic target partnering deals. Analyzing actual contract agreements allows assessment of the following:What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How aresalesand payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?Executive SummaryChapter 1 – IntroductionChapter 2 – Trends in therapeutic dealmaking activity2.1. Introduction2.2. Leading therapy partnering areas2.3. Top therapeutic targets for partnering 2009-2014Chapter 3 – Leading therapy deals by value3.1. Introduction3.2. Big pharma therapy partnering3.3. Big biotech therapy partneringChapter 4 – Submitting opportunities to therapeutic target partner companies4.1. How to submit an opportunity4.2. Opportunity submission template4.3. Sending emails4.4. Face to face at partnering events4.5. Online submission formsChapter 5 – Forthcoming therapeutic partnering events5.1. Forthcoming eventsChapter 6 – Top 35 therapeutic partnering targets

6.1. Introduction6.2. Therapeutic profiles1. DiabetesDiabetes partnering in numbersTop diabetes partnering deals by valueMost active diabetes partnering companies2. Pain CNSPain partnering in numbersTop pain partnering deals by valueMost active pain partnering companies3. Breast cancerBreast cancer partnering in numbersTop breast cancer partnering deals by valueMost active breast cancer partnering companies4. Alzheimer's diseaseAlzheimer's disease partnering in numbersTop Alzheimer's disease partnering deals by valueMost active Alzheimer's disease partnering companies5. Lung cancerLung cancer partnering in numbersTop lung cancer partnering deals by valueMost active lung cancer partnering companies6. Wound healingWound healing partnering in numbersTop wound healing partnering deals by valueMost active wound healing partnering companies7. HIVHIV partnering in numbersTop HIV partnering deals by valueMost active HIV partnering companies8. InflammationInflammation partnering in numbersTop Inflammation partnering deals by valueMost active inflammation partnering companies9. InfluenzaInfluenza partnering in numbersTop influenza partnering deals by valueMost active influenza partnering companies10. Prostate cancerProstate cancer partnering in numbersTop prostate cancer partnering deals by valueMost active prostate cancer partnering companies11. LeukemiaLeukemia partnering in numbersTop leukemia partnering deals by valueMost active leukemia partnering companies12. Nutrition & VitaminsNutrition & Vitamins partnering in numbersTop nutrition & vitamins partnering deals by valueMost active nutrition & vitamin partnering companies13. Solid tumorSolid tumor partnering in numbersTop solid tumors partnering deals by valueMost active solid tumor partnering companies14. Parkinson's diseaseParkinson's disease partnering in numbersTop Parkinson's disease partnering deals by valueMost active Parkinson's disease partnering companies15. Colorectal cancerColorectal cancer partnering in numbersTop colorectal cancer partnering deals by valueMost active colorectal cancer partnering companies16. Rheumatoid arthritisRheumatoid arthritis partnering in numbersTop rheumatoid arthritis partnering deals by valueMost active rheumatoid arthritis partnering companies17. Multiple sclerosisMultiple sclerosis partnering in numbersTop multiple sclerosis partnering deals by valueMost active multiple sclerosis partnering companies18. OrthopedicsOrthopedics partnering in numbersTop Orthopedics partnering deals by valueMost active Orthopedics partnering companies19. Accident & emergencyAccident & emergency partnering in numbersTop Accident & emergency partnering deals by valueMost active accident & emergency partnering companies20. Hepatitis CHepatitis C partnering in numbersTop hepatitis C partnering deals by valueMost active hepatitis C partnering companies21. TransplantationTransplantation partnering in numbersTop transplantation partnering deals by valueMost active transplantation partnering companies22. ObesityObesity partnering in numbersTop obesity partnering deals by valueMost active obesity partnering companies23. Ovarian cancerOvarian cancer partnering in numbersTop ovarian cancer partnering deals by valueMost active ovarian cancer partnering companies24. LymphomaLymphoma partnering in numbersTop lymphoma partnering deals by valueMost active lymphoma partnering companies25. TuberculosisTuberculosis partnering in numbersTop tuberculosis partnering deals by valueMost active tuberculosis partnering companies26. Spinal cordSpinal cord partnering in numbersTop spinal cord partnering deals by valueMost active spinal cord partnering companies27. Pancreatic cancerPancreatic cancer partnering in numbersTop pancreatic cancer partnering deals by valueMost active pancreatic cancer partnering companies28. CosmeticsCosmetics partnering in numbersTop cosmetics partnering deals by valueMost active cosmetics partnering companies29. AsthmaAsthma partnering in numbersTop asthma partnering deals by valueMost active asthma partnering companies30. Congestive heart failureCongestive heart failure partnering in numbersTop congestive heart failure partnering deals by valueMost active congestive heart failure partnering companies31. Rare Genetics DisordersRare Genetics Disorders partnering in numbersTop rare genetic disorders partnering deals by valueMost active rare genetic disorders partnering companies32. MalariaMalaria partnering in numbersTop malaria partnering deals by valueMost active malaria partnering companies33. MelanomaMelanoma partnering in numbersTop melanoma partnering deals by valueMost active melanoma partnering companies34. Brain cancerBrain cancer partnering in numbersTop brain cancer partnering deals by valueMost active brain cancer partnering companies35. StrokeStroke partnering in numbersTop stroke partnering deals by valueMost active stroke partnering companiesChapter 7 – ResourcesAbout Wildwood VenturesCurrent PartneringCurrent AgreementsRecent report titles from Current PartneringOrder Form – Deal Type ReportsOrder Form – Technology ReportsOrder Form – Therapy ReportsOrder Form – Upgrades to subscription access productsSee 3 separate volumes for the following appendicesAppendix volume 1Appendix 1 – Diabetes deal directory – company A-ZAppendix 2 – Pain deal directory – company A-ZAppendix 3 – Breast cancer deal directory – company A-ZAppendix 4 – Alzeimer's disease deal directory – company A-ZAppendix 5 – Lung cancer deal directory – company A-ZAppendix 6 –Wound healing deal directory – company A-ZAppendix 7 – HIV deal directory – company A-ZAppendix 8 –Inflammation deal directory – company A-ZAppendix 9 –Influenza deal directory – company A-ZAppendix volume 2Appendix 10 – Prostate cancer deal directory – company A-ZAppendix 11 – Leukemia deal directory – company A-ZAppendix 12 – Nutrition & Vitamins deal directory – company A-ZAppendix 13 – Solid tumors deal directory – company A-ZAppendix 14 – Parkinson's disease deal directory – company A-ZAppendix 15 – Colorectal cancer deal directory – company A-ZAppendix 16 – Rheumatoid arthritis deal directory – company A-ZAppendix 17 –Multiple sclerosis deal directory – company A-ZAppendix 18 –Orthopedics deal directory – company A-ZAppendix 19 – Accident & emergency deal directory – company A-ZAppendix 20 – Hepatitis C deal directory – company A-ZAppendix 21 – Transplantation deal directory – company A-ZAppendix 22 –Obesity deal directory – company A-ZAppendix 23 – Ovarian cancer deal directory – company A-ZAppendix volume 3Appendix 24 – Lymphoma deal directory – company A-ZAppendix 25 – Tuberculosis deal directory – company A-ZAppendix 26 – Spinal cord deal directory – company A-ZAppendix 27 – Pancreatic cancer deal directory – company A-Z Appendix 28 – Cosmetics deal directory – company A-Z Appendix 29 – Asthma deal directory – company A-ZAppendix 30 – Congestive heart failure deal directory – company A-ZAppendix 31 – Rare genetic disorders deal directory – company A-ZAppendix 32 – Malaria deal directory – company A-ZAppendix 33 – Melanoma deal directory – company A-ZAppendix 34 – Brain cancer deal directory – company A-ZAppendix 35 – Stroke deal directory – company A-ZAppendix 36 – Deal type definitionsAppendix 37 – Example contract documentTABLE OF FIGURESFigure 1: Partnering trends by therapy area 2009-2014Figure 2: Top most partnered therapeutics targets 2009-2014Figure 3: Top partnered therapeutic targets by financial value 2009-2014Figure 4: Leading big pharma therapy partnering deals by value, 2009-2014Figure 5: Leading big biotech therapy partnering deals by value, 2009-2014Figure 6: Typical partnering opportunity submission templateFigure 7: Diabetes: Partnering frequency 2009-2014Figure 8: Diabetes: most active dealmakersFigure 9: Diabetes: partnering deals by sectorFigure 10: Diabetes partnering deals by typeFigure 11: Diabetes partnering deals by technology typeFigure 12: Diabetes artnering deals by stage of developmentFigure 13: Diabetes partnering deals by headline valueFigure 14: Diabetes: partnering deals by upfront paymentFigure 15: Diabetes partnering deals by royalty rateFigure 16: Diabetes: partnering deals 2009-2014 – most active companiesFigure 17: Pain: Partnering frequency 2009-2014Figure 18: Pain partnering most active dealmakersFigure 19: Pain partnering deals by sectorFigure 20: Pain partnering deals by typeFigure 21: Pain partnering deals by technology typeFigure 22: Pain partnering deals by stage of developmentFigure 23: Pain partnering deals by headline valueFigure 24: Pain partnering deals by upfront paymentFigure 25: Pain partnering deals by royalty rateFigure 26: Pain partnering deals 2009-2014 by most active companiesFigure 27: Breast cancer: Partnering frequency 2009-2014Figure 28: Breast cancer most active dealmakersFigure 29: Breast cancer partnering deals by sectorFigure 30: Breast cancer partnering deals by typeFigure 31: Breast cancer partnering deals by technology typeFigure 32: Breast cancer partnering deals by stage of developmentFigure 33: Breast cancer partnering deals by headline valueFigure 34: Breast cancer partnering deals by upfront paymentFigure 35: Breast cancer partnering deals by royalty rateFigure 36: Breast cancer partnering deals 2009-2014 by most active companiesFigure 37: Alzheimer's disease: Partnering frequency 2009-2014Figure 38: Alzheimer's disease most active dealmakersFigure 39: Alzheimer's disease partnering deals by sectorFigure 40: Alzheimer's disease partnering deals by typeFigure 41: Alzheimer's disease partnering deals by technology typeFigure 42: Alzheimer's disease partnering deals by stage of developmentFigure 43: Alzheimer's disease partnering deals by headline valueFigure 44: Alzheimer's disease partnering deals by upfront paymentFigure 45: Alzheimer's disease partnering deals by royalty rateFigure 46: Alzheimer's partnering deals 2009-2014 by most active companiesFigure 47: Lung cancer: Partnering frequency 2009-2014Figure 48: Lung cancer most active dealmakersFigure 49: Lung cancer partnering deals by sectorFigure 50: Lung cancer partnering deals by typeFigure 51: Lung cancer partnering deals by technology typeFigure 52: Lung cancer partnering deals by stage of developmentFigure 53: Lung cancer partnering deals by headline valueFigure 54: Lung cancer partnering deals by upfront paymentFigure 55: Lung cancer partnering deals by royalty rateFigure 56: Lung cancer partnering deals 2009-2014 by most active companiesFigure 57: Wound healing: Partnering frequency 2009-2014Figure 58: Wound healing most active dealmakersFigure 59: Wound healing partnering deals by sectorFigure 60: Wound healing partnering deals by typeFigure 61: Wound healing partnering deals by technology typeFigure 62: Wound healing partnering deals by stage of developmentFigure 63: Wound healing partnering deals by headline valueFigure 64: Wound healing partnering deals by upfront paymentFigure 65: Wound healing partnering deals by royalty rateFigure 66: Wound healing partnering deals 2009-2014 by most active companiesFigure 67: HIV: Partnering frequency 2009-2014Figure 68: HIV most active dealmakersFigure 69: HIV partnering deals by sectorFigure 70: HIV partnering deals by typeFigure 71: HIV partnering deals by technology typeFigure 72: HIV partnering deals by stage of developmentFigure 73: HIV partnering deals by headline valueFigure 74: HIV partnering deals by upfront paymentFigure 75: HIV partnering deals by royalty rateFigure 76: HIV partnering deals 2009-2014 by most active companiesFigure 77: Inflammation: Partnering frequency 2009-2014Figure 78: Inflammation most active dealmakersFigure 79: Inflammation partnering deals by industry sectorFigure 80: Inflammation partnering deals by typeFigure 81: Inflammation partnering deals by technology typeFigure 82: Inflammation partnering deals by stage of developmentFigure 83: Inflammation partnering deals by headline valueFigure 84: Inflammation partnering deals by upfront paymentFigure 85: Inflammation partnering deals by royalty rateFigure 86: Inflammation partnering deals 2009-2014 by most active companiesFigure 87: Influenza: Partnering frequency 2009-2014Figure 88: Influenza most active dealmakersFigure 89: Influenza partnering deals by industry sectorFigure 90: Influenza partnering deals by typeFigure 91: Influenza partnering deals by technology typeFigure 92: Influenza partnering deals by stage of developmentFigure 93: Influenza partnering deals by headline valueFigure 94: Influenza partnering deals by upfront paymentFigure 95: Influenza partnering deals by royalty rateFigure 96: Influenza partnering deals 2009-2014 by most active companiesFigure 97: Prostate cancer: Partnering frequency 2009-2014Figure 98: Prostate cancer most active dealmakersFigure 99: Prostate cancer partnering deals by industry sectorFigure 100: Prostate cancer partnering deals by typeFigure 101: Prostate cancer partnering deals by technology typeFigure 102: Prostate cancer partnering deals by stage of developmentFigure 103: Prostate cancer partnering deals by headline valueFigure 104: Prostate cancer partnering deals by upfront paymentFigure 105: Prostate cancer partnering deals by royalty rateFigure 106: Prostate cancer partnering deals 2009-2014 by most active companiesFigure 107: Leukemia: Partnering frequency 2009-2014Figure 108: Leukemia most active dealmakersFigure 109: Leukemia partnering deals by industry sectorFigure 110: Leukemia partnering deals by typeFigure 111: Leukemia partnering deals by technology typeFigure 112: Leukemia partnering deals by stage of developmentFigure 113: Leukemia partnering deals by headline valueFigure 114: Leukemia partnering deals by upfront paymentFigure 115: Leukemia partnering deals by royalty rateFigure 116: Leukemia partnering deals 2009-2014 by most active companiesFigure 117: Nutrition & Vitamins: Partnering frequency 2009-2014Figure 118: Nutrition & Vitamins most active dealmakersFigure 119: Nutrition & Vitamins partnering deals by sectorFigure 120: Nutrition & Vitamins partnering deals by typeFigure 121: Nutrition & Vitamins partnering deals by technology typeFigure 122: Nutrition & Vitamins partnering deals by stage of developmentFigure 123: Nutrition & Vitamins partnering deals by headline valueFigure 124: Nutrition & Vitamins partnering deals by upfront paymentFigure 125: Nutrition & Vitamins partnering deals by royalty rateFigure 126: Nutrition & Vitamins partnering deals 2009-2014 by most active companiesFigure 127: Solid tumor: Partnering frequency 2009-2014Figure 128: Solid tumor most active dealmakersFigure 129: Solid tumor partnering deals by industry sectorFigure 130: Solid tumor partnering deals by typeFigure 131: Soid tumor partnering deals by technology typeFigure 132: Solid tumor partnering deals by stage of developmentFigure 133: Solid tumor partnering deals by headline valueFigure 134: Solid tumor partnering deals by upfront paymentFigure 135: Solid tumor partnering deals by royalty rateFigure 136: Solid tumor partnering deals 2009-2014 by most active companiesFigure 137: Parkinson's disease: Partnering frequency 2009-2014Figure 138: Parkinson's disease most active dealmakersFigure 139: Parkinson's disease partnering deals by industry sectorFigure 140: Parkinson's disease partnering deals by typeFigure 141: Parkinson's disease partnering deals by technology typeFigure 142: Parkinson's disease partnering deals by stage of developmentFigure 143: Parkinson's disease partnering deals by headline valueFigure 144: Parkinson's disease partnering deals by upfront paymentFigure 145: Parkinson's disease partnering deals by royalty rateFigure 146: Parkinson's disease partnering deals 2009-2014 by most active companiesFigure 147: Colorectal cancer: Partnering frequency 2009-2014Figure 148: Colorectal cancer most active dealmakersFigure 149: Colorectal cancer partnering deals by industry sectorFigure 150: Colorectal cancer partnering deals by typeFigure 151: Colorectal cancer partnering deals by technology typeFigure 152: Colorectal cancer partnering deals by stage of developmentFigure 153: Colorectal cancer partnering deals by headline valueFigure 154: Coloretal cancer partnering deals by upfront paymentFigure 155: Colorectal cancer partnering deals by royalty rateFigure 156: Colorectal cancer partnering deals 2009-2014 by most active companiesFigure 157: Rheumatoid arthritis: Partnering frequency 2009-2014Figure 158: Rheumatoid arthritis most active dealmakersFigure 159: Rheumatoid arthritis partnering deals by industry sectorFigure 160: Rheumatoid arthritis partnering deals by typeFigure 161: Rheumatoid arthritis partnering deals by technology typeFigure 162: Rheumatoid arthritis partnering deals by stage of developmentFigure 163: Rheumatoid arthritis partnering deals by headline valueFigure 164: Rheumatoid arthritis partnering deals by upfront paymentFigure 165: Rheumatoid arthritis partnering deals by royalty rateFigure 166: Rheumatoid arthritis partnering deals 2009-2014 by most active companiesFigure 167: Multiple sclerosis: Partnering frequency 2009-2014Figure 168: Multiple sclerosis most active dealmakersFigure 169: Multiple sclerosis partnering deals by industry sectorFigure 170: Multiple sclerosis partnering deals by typeFigure 171: Multiple sclerosis partnering deals by technology typeFigure 172: Multiple sclerosis partnering deals by stage of developmentFigure 173: Multiple sclerosis partnering deals by headline valueFigure 174: Multiple sclerosis partnering deals by upfront paymentFigure 175: Multiple sclerosis partnering deals by royalty rateFigure 176: Multiple sclerosis partnering deals 2009-2014 by most active companiesFigure 177: Orthopedics: Partnering frequency 2009-2014Figure 178: Orthopedics most active dealmakersFigure 179: Orthopedics partnering deals by industry sectorFigure 180: Orthopedics partnering deals by typeFigure 181: Orthopedics partnering deals by technology typeFigure 182: Orthopedics partnering deals by stage of developmentFigure 183: Orthopedics partnering deals by headline valueFigure 184: Orthopedics partnering deals by upfront paymentFigure 185: Orthopedics partnering deals by royalty rateFigure 186: Orthopedics partnering deals 2009-2014 by most active companiesFigure 187: Accident & emergency: Partnering frequency 2009-2014Figure 188: Accident & emergency most active dealmakersFigure 189: Accident & emergency partnering deals by industry sectorFigure 190: Accident & emergency partnering deals by typeFigure 191: Accident & emergency partnering deals by technology typeFigure 192: Accident & emergency partnering deals by stage of developmentFigure 193: Accident & emergency partnering deals by headline valueFigure 194: Accident & emergency partnering deals by upfront paymentFigure 195: Accident & emergency partnering deals by royalty rateFigure 196: Accident & emergency partnering deals 2009-2014 by most active companiesFigure 197: Hepatitis C: Partnering frequency 2009-2014Figure 198: Hepatitis C most active dealmakersFigure 199: Hepatitis C partnering deals by industry sectorFigure 200: Hepatitis C partnering deals by typeFigure 201: Hepatitis C partnering deals by technology typeFigure 202: Hepatitis C partnering deals by stage of developmentFigure 203: Hepatitis C partnering deals by headline valueFigure 204: Hepatitis C partnering deals by upfront paymentFigure 205: Hepatitis C partnering deals by royalty rateFigure 206: Hepatitis C partnering deals 2009-2014 by most active companiesFigure 207: Transplantation: Partnering frequency 2009-2014Figure 208: Transplantation most active dealmakersFigure 209: Transplantation partnering deals by industry sectorFigure 210: Transplantation partnering deals by typeFigure 211: Transplantation partnering deals by technology typeFigure 212: Transplantation partnering deals by stage of developmentFigure 213: Transplantation partnering deals by headline valueFigure 214: Transplantation partnering deals by upfront paymentFigure 215: Transplantation partnering deals by royalty rateFigure 216: Transplantation partnering deals 2009-2014 by most active companiesFigure 217: Obesity: Partnering frequency 2009-2014Figure 218: Obesity most active dealmakersFigure 219: Obesity partnering deals by industry sectorFigure 220: Obesity partnering deals by typeFigure 221: Obesity partnering deals by technology typeFigure 222: Obesity partnering deals by stage of developmentFigure 223: Obesity partnering deals by headline valueFigure 224: Obesity partnering deals by upfront paymentFigure 225: Obesity partnering deals by royalty rateFigure 226: Obesity partnering deals 2009-2014 by most active companiesFigure 227: Ovarian cancer: Partnering frequency 2009-2014Figure 228: Ovarian cancer most active dealmakersFigure 229: Ovarian cancer partnering deals by industry sectorFigure 230: Ovarian cancer partnering deals by typeFigure 231: Ovarian cancer partnering deals by technology typeFigure 232: Ovarian cancer partnering deals by stage of developmentFigure 233: Ovarian cancer partnering deals by headline valueFigure 234: Ovarian cancer partnering deals by upfront paymentFigure 235: Ovarian cancer partnering deals by royalty rateFigure 236: Ovarian cancer partnering deals 2009-2014 by most active companiesFigure 237: Lymphoma: Partnering frequency 2009-2014Figure 238: Lymphoma most active dealmakersFigure 239: Lymphoma partnering deals by industry sectorFigure 240: Lymphoma partnering deals by typeFigure 241: Lymphoma partnering deals by technology typeFigure 242: Lymphoma partnering deals by stage of developmentFigure 243: Lymphoma partnering deals by headline valueFigure 244: Lymphoma partnering deals by upfront paymentFigure 245: Lymphoma partnering deals by royalty rateFigure 246: Lymphoma partnering deals 2009-2014 by most active companiesFigure 247: Tuberculosis: Partnering frequency 2009-2014Figure 248: Tuberculosis most active dealmakersFigure 249: Tuberculosis partnering deals by industry sectorFigure 250: Tuberculosis partnering deals by typeFigure 251: Tuberculosis partnering deals by technology typeFigure 252: Tuberculosis partnering deals by stage of developmentFigure 253: Tuberculosis partnering deals by headline valueFigure 254: Tuberculosis partnering deals by upfront paymentFigure 255: Tuberculosis partnering deals by royalty rateFigure 256: Tuberculosis partnering deals 2009-2014 by most active companiesFigure 257: Spinal cord: Partnering frequency 2009-2014Figure 258: Spinal cord most active dealmakersFigure 259: Spinal cord partnering deals by industry sectorFigure 260: Spinal cord partnering deals by typeFigure 261: Spinal cord partnering deals by technology typeFigure 262: Spinal cord partnering deals by stage of developmentFigure 263: Spinal cord partnering deals by headline valueFigure 264: Spinal cord partnering deals by upfront paymentFigure 265: Spinal cord partnering deals by royalty rateFigure 266: Spinal cord partnering deals 2009-2014 by most active companiesFigure 267: Pancreatic cancer: Partnering frequency 2009-2014Figure 268: Pancreatic cancer most active dealmakersFigure 269: Pancreatic cancer partnering deals by industry sectorFigure 270: Pancreatic cancer partnering deals by typeFigure 271: Pancreatic cancer partnering deals by technology typeFigure 272: Pancreatic cancer partnering deals by stage of developmentFigure 273: Pancreatic cancer partnering deals by headline valueFigure 274: Pancreatic cancer partnering deals by upfront paymentFigure 275: Pancreatic cancer partnering deals by royalty rateFigure 276: pancreatic cancer partnering deals 2009-2014 by most active companiesFigure 277: Cosmetics: Partnering frequency 2009-2014Figure 278: Cosmetics most active dealmakersFigure 279: Cosmetics partnering deals by industry sectorFigure 280: Cosmetics partnering deals by typeFigure 281: Cosmetics partnering deals by technology typeFigure 282: Cosmetics partnering deals by stage of developmentFigure 283: Cosmetics partnering deals by headline valueFigure 284: Cosmetics partnering deals by upfront paymentFigure 285: Cosmetics partnering deals by royalty rateFigure 286: Cosmetics partnering deals 2009-2014 by most active companiesFigure 287: Asthma: Partnering frequency 2009-2014Figure 288: Asthma most active dealmakersFigure 289: Asthma partnering deals by industry sectorFigure 290: Asthma partnering deals by typeFigure 291: Asthma partnering deals by technology typeFigure 292: Asthma partnering deals by stage of developmentFigure 293: Asthma partnering deals by headline valueFigure 294: Asthma partnering deals by upfront paymentFigure 295: Asthma partnering deals by royalty rateFigure 296: Asthma partnering deals 2009-2014 by most active companiesFigure 297: Congestive heart failure: Partnering frequency 2009-2014Figure 298: Congestive heart failure most active dealmakersFigure 299: Congestive heart failure partnering deals by industry sectorFigure 300: Congestive heart failure partnering deals by typeFigure 301: Congestive heart failure partnering deals by technology typeFigure 302: Congestive heart failure partnering deals by stage of developmentFigure 303: Congestive heart failure partnering deals by headline valueFigure 304: Congestive heart failure partnering deals by upfront paymentFigure 305: Congestive heart failure partnering deals by royalty rateFigure 306: Congestive heart failure partnering deals 2009-2014 by most active companiesFigure 307: Rare genetic disorders: Partnering frequency 2009-2014Figure 308: Rare genetic disorders most active dealmakersFigure 309: Rare genetic disorders partnering deals by industry sectorFigure 310: Rare genetic disorders partnering deals by typeFigure 311: Rare genetic disorders partnering deals by technology typeFigure 312: Rare genetic disorders partnering deals by stage of developmentFigure 313: Rare genetic disorders partnering deals by headline valueFigure 314: Rare genetic disorders partnering deals by upfront paymentFigure 315: Rare genetic disorders partnering deals by royalty rateFigure 316: Rare genetic disorders partnering deals 2009-2014 by most active companiesFigure 317: Malaria: Partnering frequency 2009-2014Figure 318: Malaria most active dealmakersFigure 319: Malaria partnering deals by industry sectorFigure 320: Malaria partnering deals by typeFigure 321: Malaria partnering deals by technology typeFigure 322: Malaria partnering deals by stage of developmentFigure 323: Malaria partnering deals by headline valueFigure 324: Malaria partnering deals by upfront paymentFigure 325: Malaria partnering deals by royalty rateFigure 326: Malaria partnering deals 2009-2014 by most active companiesFigure 327: Melanoma: Partnering frequency 2009-2014Figure 328: Melanoma most active dealmakersFigure 329: Melanoma partnering deals by industry sectorFigure 330: Melanoma partnering deals by typeFigure 331: Melanoma partnering deals by technology typeFigure 332: Melanoma partnering deals by stage of developmentFigure 333: Melanoma partnering deals by headline valueFigure 334: Melanoma partnering deals by upfront paymentFigure 335: Melanoma partnering deals by royalty rateFigure 336: Melanoma partnering deals 2009-2014 by most active companiesFigure 337: Brain cancer: Partnering frequency 2009-2014Figure 338: Brain cancer most active dealmakersFigure 339: Brain cancer partnering deals by industry sectorFigure 340: Brain cancer partnering deals by typeFigure 341: Brain cancer partnering deals by technology typeFigure 342: Brain cancer partnering deals by stage of developmentFigure 343: Brain cancer partnering deals by headline valueFigure 344: Brain cancer partnering deals by upfront paymentFigure 345: Brain cancer partnering deals by royalty rateFigure 346: Brain cancer partnering deals 2009-2014 by most active companiesFigure 347: Stroke: Partnering frequency 2009-2014Figure 348: Stroke most active dealmakersFigure 349: Stroke partnering deals by industry sectorFigure 350: Stroke partnering deals by typeFigure 351: Stroke partnering deals by technology typeFigure 352: Stroke artnering deals by stage of developmentFigure 353: Stroke partnering deals by headline valueFigure 354: Stroke partnering deals by upfront paymentFigure 355: Stroke partnering deals by royalty rateFigure 356: stroke partnering deals 2009-2014 by most active companiesFigure 357: Online partnering resources Read the full report: Trends in Therapeutic Partnering https://www.reportbuyer.com/product/1593890/Trends-in-Therapeutic-Partnering.htmlFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs